VCP and non-small cell lung carcinoma: Overall, our findings not only support previous studies [1–5, 8, 10, 11, 19] but also provide substantial evidence that selective dendrimer-based VCP-inhibition is a promising therapeutic strategy for controlling the NSCLC progression.